Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development

The diagnosis and management of drug‐induced liver injury (DILI) remains a challenge in clinical trials in drug development. The qualification of emerging biomarkers capable of predicting DILI soon after the initiation of treatment, differentiating DILI from underlying liver disease, identifying the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology and therapeutics 2020-02, Vol.107 (2), p.333-346
Hauptverfasser:	Roth, Sharin E., Avigan, Mark I., Bourdet, David, Brott, David, Church, Rachel, Dash, Ajit, Keller, Douglas, Sherratt, Philip, Watkins, Paul B., Westcott‐Baker, Lucas, Lentini, Silvia, Merz, Michael, Ramaiah, Lila, Ramaiah, Shashi K., Stanley, Ann Marie, Marcinak, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Chemical and Drug Induced Liver Injury - blood Chemical and Drug Induced Liver Injury - diagnosis Clinical Trials as Topic - standards Drug Development - methods Drug Development - standards Humans Informed Consent Liver Function Tests Phenotype Review Reviews Specimen Handling - methods Specimen Handling - standards
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!